74037-56-2

Usage

Uses

Used in Pharmaceutical Industry:
2-[(2-Methoxyethyl)amino]-5-nitropyridine serves as an intermediate in the synthesis of pharmaceuticals. Its unique structure allows it to be a key component in the development of various medicinal compounds, contributing to the creation of drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2-[(2-Methoxyethyl)amino]-5-nitropyridine is utilized as an intermediate for the synthesis of agrochemicals. Its role in formulating pesticides, herbicides, and other agricultural chemicals is crucial for enhancing crop protection and yield.
Used as a Building Block in Organic Chemistry:
2-[(2-Methoxyethyl)amino]-5-nitropyridine is employed as a versatile building block in organic chemistry. It is involved in a range of chemical reactions, enabling the production of complex molecules with diverse applications across various industries, including pharmaceutical and agricultural sectors.

InChI:InChI=1/C8H11N3O3/c1-14-5-4-9-8-3-2-7(6-10-8)11(12)13/h2-3,6H,4-5H2,1H3,(H,9,10)

Upstream product

• 5418-51-9 5-nitro-2-hydroxypyridine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 109-85-3 2-methoxyethylamine 

Downstream Products

• 926197-50-4 N₂-(2-methoxyethyl)pyridine-2,5-diamine 
• 1419603-44-3 phenyl 6-(2-methoxyethylamino)pyridin-3-ylcarbamate 
• 1419598-98-3 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(6-(2-methoxyethylamino)pyridin-3-yl)urea 
• 1419598-95-0 1-((3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methyl)-3-(6-(2-methoxyethylamino)pyridin-3-yl)urea 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Substituted heteroaromatic pyrazole-containing carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also to a method of using these compounds for treating and/or inhibiting pain and further diseases and/or disorders.

SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES

The invention relates to heterocyclic aza derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted Heterocyclic Aza Compounds

Heterocyclic aza compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also methods of using these compounds for the treatment and/or inhibition of pain and further diseases and/or disorders.

Discovery and optimization of 2-phenyloxazole derivatives as diacylglycerol acyltransferase-1 inhibitors

In a discovery effort to find safe and effective DGAT-1 inhibitors, we have identified 2-phenyloxazole 4-carboxamide 1 as a conformationally constrained analog of a hydrazide hit, which was previously identified from high-throughput screening. Further optimization of this series has led to chemically more stable 2-phenyloxazole-based DGAT-1 inhibitor 25 with improved solubility, cell-based activity, and pharmacokinetic properties. Compound 25 also demonstrated in vivo efficacy in a diet-induced obesity (DIO) rat model.